K. V. T. Gopal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
K. V. T. Gopal has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
D Sarvani
1 shared publicationG Raghu Rama Rao
1 shared publicationG Raghurama Rao
Department of Dermatology, Surya Skin Care and Research Center, Visakhapatnam, Andhra Pradesh, India
1 shared publicationG Shanti
1 shared publicationG. Deepika Raj
Maharajah’s Institute of Medical Sciences, Nellimarla, Vizianagaram Dt., Andhra Pradesh, India
1 shared publicationGraghu Rama Rao
1 shared publication
Latest Publications
- Open Access
- 31 May 2015
- Published by Siddharth Health Research and Social Welfare Society in International Journal of Medical Research & Review
- Vol. 3 (4) , 404-408
Prevalence of metabolic syndrome in Psoriasis – a case control study
Introduction: Recently, associations between psoriasis and metabolic disorders such as obesity, diabetes, and atherogenic dyslipidemia have been recognized. The present study was performed to know the prevalence of metabolic syndrome and its individual components in Psoriatic patients and compare them with age and sex matched controls. Methods: The study included 60 psoriatic patients and 60 age and sex matched controls. Severity of psoriasis was assessed according to psoriasis area and severity index (PASI) score. Waist circumference, blood pressure, fasting plasma glucose, serum cholesterol, HDL, LDL, VLDL and triglycerides were recodrded in all patients and controls. Metabolic syndrome was diagnosed by the presence of three or more of the five criteria of the 2005 revised National Cholesterol Education Programme’s Adult Treatment Panel III . Statistical analysis of the data was performed. Results: Prevalence of metabolic syndrome was seen in 20 cases (33.3%) compared to 9 (15%) controls which was statistically significant (P = 0.019). Metabolic syndrome, high fasting blood glucose, high triglyceride levels and low HDL levels were significantly more in cases than controls. There was no significant difference in the prevalence of abdominal obesity and hypertension among cases and controls. Conclusion: There is a need for regular evaluation of psoriatic patients, even younger patients and those with mild disease, for the presence of any of the components of metabolic syndrome. Dermatologists should screen all psoriasis patients to detect the existence of comorbid conditions such as metabolic syndrome and its individual components.
- 31 May 2015
- Published by Siddharth Health Research and Social Welfare Society in International Journal of Medical Research & Review
- Vol. 3 (4) , 404-408
Open AccessPrevalence of metabolic syndrome in Psoriasis – a case control study
Introduction: Recently, associations between psoriasis and metabolic disorders such as obesity, diabetes, and atherogenic dyslipidemia have been recognized. The present study was performed to know the prevalence of metabolic syndrome and its individual components in Psoriatic patients and compare them with age and sex matched controls. Methods: The study included 60 psoriatic patients and 60 age and sex matched controls. Severity of psoriasis was assessed according to psoriasis area and severity index (PASI) score. Waist circumference, blood pressure, fasting plasma glucose, serum cholesterol, HDL, LDL, VLDL and triglycerides were recodrded in all patients and controls. Metabolic syndrome was diagnosed by the presence of three or more of the five criteria of the 2005 revised National Cholesterol Education Programme’s Adult Treatment Panel III . Statistical analysis of the data was performed. Results: Prevalence of metabolic syndrome was seen in 20 cases (33.3%) compared to 9 (15%) controls which was statistically significant (P = 0.019). Metabolic syndrome, high fasting blood glucose, high triglyceride levels and low HDL levels were significantly more in cases than controls. There was no significant difference in the prevalence of abdominal obesity and hypertension among cases and controls. Conclusion: There is a need for regular evaluation of psoriatic patients, even younger patients and those with mild disease, for the presence of any of the components of metabolic syndrome. Dermatologists should screen all psoriasis patients to detect the existence of comorbid conditions such as metabolic syndrome and its individual components.
- Open Access
- 1 January 2014
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 5 (4) , 456-60
Increased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study
Background: Though it is well-known that vitiligo is associated with other autoimmune disorders, few Indian studies have focused on the relation between vitiligo, autoimmune thyroid dysfunction and diabetes mellitus. Materials and Methods: This case-control study included 150 new cases of vitiligo and 100 age and sex-matched controls. A complete history and thorough dermatological examination was done. Serum samples from both patients and controls were collected and assayed for triiodothyronine, thyroxine, thyroid-stimulating hormone, anti-thyroid antibodies-anti-thyroid peroxidase and anti-thyroglobulin and fasting plasma glucose. Results: Thyroid hormonal profile revealed autoimmune thyroid dysfunction manifesting as hypothyroidism in 30 (20%) vitiligo patients and two controls (2%). Diabetes mellitus was present in 24 (16%) vitiligo patients and five controls. Seven (4.7%) patients had both hypothyroidism and diabetes mellitus. Conclusion: There is a clear association between vitiligo, autoimmune hypothyroidism and diabetes mellitus. It would be very useful to screen for thyroid dysfunction and diabetes mellitus in all patients with vitiligo.
- 1 January 2014
- Published by Medknow in Indian Dermatology Online Journal
- Vol. 5 (4) , 456-60
Open AccessIncreased prevalence of thyroid dysfunction and diabetes mellitus in Indian vitiligo patients: A case-control study
Background: Though it is well-known that vitiligo is associated with other autoimmune disorders, few Indian studies have focused on the relation between vitiligo, autoimmune thyroid dysfunction and diabetes mellitus. Materials and Methods: This case-control study included 150 new cases of vitiligo and 100 age and sex-matched controls. A complete history and thorough dermatological examination was done. Serum samples from both patients and controls were collected and assayed for triiodothyronine, thyroxine, thyroid-stimulating hormone, anti-thyroid antibodies-anti-thyroid peroxidase and anti-thyroglobulin and fasting plasma glucose. Results: Thyroid hormonal profile revealed autoimmune thyroid dysfunction manifesting as hypothyroidism in 30 (20%) vitiligo patients and two controls (2%). Diabetes mellitus was present in 24 (16%) vitiligo patients and five controls. Seven (4.7%) patients had both hypothyroidism and diabetes mellitus. Conclusion: There is a clear association between vitiligo, autoimmune hypothyroidism and diabetes mellitus. It would be very useful to screen for thyroid dysfunction and diabetes mellitus in all patients with vitiligo.
- Open Access
- 1 January 2010
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 76 (5) , 569-71
Herpes zoster motor neuropathy: A clinical and electrophysiological study
- 1 January 2010
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 76 (5) , 569-71
Open AccessHerpes zoster motor neuropathy: A clinical and electrophysiological study
- Open Access
- 1 January 2009
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 75 (2) , 162-6
Evaluation of narrow-band UVB phototherapy in 150 patients with vitiligo
Background: Very few studies have been performed to evaluate the efficacy and safety of narrow-band ultraviolet B (NBUVB) therapy in Indian patients with vitiligo and are of small sample size. Aims: The purpose of this study is to know the efficacy and safety of NBUVB in 150 vitiligo patients of various age groups. Methods: One hundred fifty patients (69 males, 81 females), aged 3-70 years, with vitiligo were treated twice weekly with NBUVB. The starting dose was 250 mJ/cm 2 in adults and 150 mJ/cm 2 in children, with 20% dose increments at each subsequent visit given for a maximum period of 1 year and were followed-up for 6 months for stability of repigmentation. Statistical methods were employed to establish the relation between the response and the number of exposures, duration of treatment, cumulative dose and the compliance. Results: Analysis of our study showed that a majority of our cases, about 73, achieved 25-75% repigmentation, with an average of 51 19 exposures, 51 had 75% repigmentation, with an average of 74 24 exposures. Good response to therapy was directly associated with good compliance, more number of exposures and increasing cumulative dose, which was statistically significant (P Conclusion: Our study proves that NBUVB therapy is an effective and safe tool in the management of vitiligo, with good stability of repigmentation and cosmetic appearance.
- 1 January 2009
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 75 (2) , 162-6
Open AccessEvaluation of narrow-band UVB phototherapy in 150 patients with vitiligo
Background: Very few studies have been performed to evaluate the efficacy and safety of narrow-band ultraviolet B (NBUVB) therapy in Indian patients with vitiligo and are of small sample size. Aims: The purpose of this study is to know the efficacy and safety of NBUVB in 150 vitiligo patients of various age groups. Methods: One hundred fifty patients (69 males, 81 females), aged 3-70 years, with vitiligo were treated twice weekly with NBUVB. The starting dose was 250 mJ/cm 2 in adults and 150 mJ/cm 2 in children, with 20% dose increments at each subsequent visit given for a maximum period of 1 year and were followed-up for 6 months for stability of repigmentation. Statistical methods were employed to establish the relation between the response and the number of exposures, duration of treatment, cumulative dose and the compliance. Results: Analysis of our study showed that a majority of our cases, about 73, achieved 25-75% repigmentation, with an average of 51 19 exposures, 51 had 75% repigmentation, with an average of 74 24 exposures. Good response to therapy was directly associated with good compliance, more number of exposures and increasing cumulative dose, which was statistically significant (P Conclusion: Our study proves that NBUVB therapy is an effective and safe tool in the management of vitiligo, with good stability of repigmentation and cosmetic appearance.
- Open Access
- 1 January 2007
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 73 (3) , 162-5
Vitiligo: A part of a systemic autoimmune process
Background : Recent clinical and animal experimental studies postulate that the pathogenetic mechanisms of vitiligo could be of systemic origin as vitiligo is associated with ocular and auditory abnormalities as well as other autoimmune disorders.Hence, we studied genetic factors, systemic associations, ocular and auditory abnormalities of vitiligo. Methods: The study group included 150 new cases of various types of vitiligo. One hundred age- and sex-matched nonvitiligo cases were included as controls in the study. A complete family history was taken for all patients. Examination was carried out taking note of the type of vitiligo and approximate percentage of body surface involved. All relevant laboratory investigations, a thorough audiological examination including pure tone audiometry and a complete ophthalmologic examination were carried out in all patients and controls. Statistical analysis was done using the Chi square test. Results: Fifty-four vitiligo patients (36%) had a family history of vitiligo. Anemia was present in 30 (20%) vitiligo patients but only in five (5%) controls, a difference that was statistically significant (c2 = 15.8, P < 0.001). Diabetes mellitus was present in 24 (16%) vitiligo patients and only 2 (2%) of controls (Chi square, c2 = 12.4, P < 0.001). Hypothyroidism and alopecia areata were present in 18 (12%) and 11 (7.4%) vitiligo patients respectively and none of the controls. Hypoacusis was seen in 30 (20%) vitiligo patients and two (2%) controls (c2 = 8.19, P < 0.005). Twenty-four vitiligo patients (16%) and five controls (5%) had specific ocular abnormalities like uveitis, iris and retinal pigmentary abnormalities (c2 = 7.39, P < 0.001). Conclusion: This study demonstrates statistically significant clinical evidence confirming that vitiligo is a part of systemic autoimmune process.
- 1 January 2007
- Published by Scientific Scholar in Indian Journal of Dermatology, Venereology and Leprology
- Vol. 73 (3) , 162-5
Open AccessVitiligo: A part of a systemic autoimmune process
Background : Recent clinical and animal experimental studies postulate that the pathogenetic mechanisms of vitiligo could be of systemic origin as vitiligo is associated with ocular and auditory abnormalities as well as other autoimmune disorders.Hence, we studied genetic factors, systemic associations, ocular and auditory abnormalities of vitiligo. Methods: The study group included 150 new cases of various types of vitiligo. One hundred age- and sex-matched nonvitiligo cases were included as controls in the study. A complete family history was taken for all patients. Examination was carried out taking note of the type of vitiligo and approximate percentage of body surface involved. All relevant laboratory investigations, a thorough audiological examination including pure tone audiometry and a complete ophthalmologic examination were carried out in all patients and controls. Statistical analysis was done using the Chi square test. Results: Fifty-four vitiligo patients (36%) had a family history of vitiligo. Anemia was present in 30 (20%) vitiligo patients but only in five (5%) controls, a difference that was statistically significant (c2 = 15.8, P < 0.001). Diabetes mellitus was present in 24 (16%) vitiligo patients and only 2 (2%) of controls (Chi square, c2 = 12.4, P < 0.001). Hypothyroidism and alopecia areata were present in 18 (12%) and 11 (7.4%) vitiligo patients respectively and none of the controls. Hypoacusis was seen in 30 (20%) vitiligo patients and two (2%) controls (c2 = 8.19, P < 0.005). Twenty-four vitiligo patients (16%) and five controls (5%) had specific ocular abnormalities like uveitis, iris and retinal pigmentary abnormalities (c2 = 7.39, P < 0.001). Conclusion: This study demonstrates statistically significant clinical evidence confirming that vitiligo is a part of systemic autoimmune process.